Lisa R Bell

US Patent:

6416759, Jul 9, 2002

Filed:

Sep 30, 1999

Appl. No.:

09/410485

Inventors:

Gary L. Firestone - Berkeley CA
Patricia Buse - San Francisco CA
Lisa M. Bell - San Mateo CA
Meredith L. L. Leong - Berkeley CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241551, 4241301, 4241411, 4241421, 4241431, 4241521, 435 4, 435 71, 435 721, 435 723, 436 64, 436512, 514 1, 514 2, 514 12, 514 42, 514 43, 514 44

Abstract:

The invention provides methods and compositions relating to activated Sgk and the association of activated Sgk activity with proliferating cells, including methods for inhibiting the growth of an undesirably proliferating cell by contacting the cell with a specific inhibitor of activated Sgk whereby the amount of activated Sgk activity in the cell is reduced. Specific inhibitors are disclosed, including dominant negative mutants of activated Sgk, an Sgk mutant or fragment thereof comprising an unphosphorylatable residue corresponding to Thr 256 of native Sgk, and an active Sgk-specific antibody or antibody fragment, especially intrabody, etc. A wide variety of methods may be used to contact the target cell with the inhibitor, especially introducing into the cell a polynucleotide encoding the inhibitor under conditions whereby the inhibitor is expressed in the cell.

US Patent:

7087392, Aug 8, 2006

Filed:

Jul 4, 2002

Appl. No.:

10/189976

Inventors:

Gary L. Firestone - Berkeley CA, US
Patricia Buse - San Francisco CA, US
Lisa M. Bell - San Mateo CA, US
Meredith L. L. Leong - Berkeley CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 33/53

US Classification:

435 71, 435 723

Abstract:

The invention provides methods and compositions relating to activated Sgk and the association of activated Sgk activity with proliferating cells, including methods for inhibiting the growth of an undesirably proliferating cell by contacting the cell with a specific inhibitor of activated Sgk whereby the amount of activated Sgk activity in the cell is reduced. Specific inhibitors are disclosed, including dominant negative mutants of activated Sgk, an Sgk mutant or fragment thereof comprising an unphosphorylatable residue corresponding to Thr256 of native Sgk, and an active Sgk-specific antibody or antibody fragment, especially intrabody, etc. A wide variety of methods may be used to contact the target cell with the inhibitor, especially introducing into the cell a polynucleotide encoding the inhibitor under conditions whereby the inhibitor is expressed in the cell.